Chronic Myeloid Leukemia (CML) Bone Marrow Mononuclear Cells
About:Chronic Myeloid Leukemia (CML) Bone Marrow Mononuclear Cells - cryopreserved BMMCs isolated from clinically confirmed CML donors. The BCR-ABL1 fusion originates in a pluripotent marrow hematopoietic stem cell, making marrow cytogenetics central to diagnosis, clonal evolution monitoring, and TKI response assessment. Ideal for BCR-ABL1 and clonal evolution studies. Stratification by disease phase and TKI treatment history.
About Chronic Myeloid Leukemia (CML) Bone Marrow Mononuclear Cells
Chronic Myeloid Leukemia (CML) Bone Marrow Mononuclear Cells for Leukemia Research
Chronic myeloid leukemia (CML) bone marrow mononuclear cells (BMMCs) are isolated by density-gradient separation from bone marrow aspirate, capturing the full spectrum of marrow-resident hematopoietic stem, progenitor, and precursor cells that peripheral blood samples do not contain. Samples come from consented donors under IRB-approved protocols, each clinically diagnosed with CML — a myeloproliferative neoplasm driven by the BCR-ABL1 fusion gene.
CML Biology and Why Bone Marrow
- CML arises from the BCR-ABL1 fusion oncogene originating in a pluripotent hematopoietic stem cell within the bone marrow, giving rise to unchecked myeloid proliferation.
- Marrow cytogenetic analysis is central to diagnosis (identifying the Philadelphia chromosome) and to detecting additional chromosomal abnormalities associated with clonal evolution and disease progression to accelerated or blast phase.
- While peripheral blood BCR-ABL1 transcript levels by qPCR are used for routine monitoring, marrow assessment remains important at diagnosis and at defined treatment milestones, including evaluation for resistance mutations.
- Tyrosine kinase inhibitor (TKI) therapy has transformed CML management, and marrow-derived material supports research into treatment-free remission, resistance mechanisms, and residual leukemic stem cell persistence.
- Leukemic stem cells in CML are relatively TKI-resistant and reside in the marrow niche, making marrow material particularly relevant to relapse and cure research.
Donor Stratification Available
- Disease phase: chronic, accelerated, or blast phase
- Philadelphia chromosome and additional cytogenetic abnormalities where documented
- TKI treatment history and molecular response status
- Resistance mutation status where documented
- Age band and sex assigned at birth
- Matched healthy bone marrow controls available
Product Features
- Isolated from clinically confirmed CML donor bone marrow aspirate
- Density-gradient purified and cryopreserved
- Research Use Only (RUO)
- IRB-approved protocols with documented consent
- Standard and custom cell quantities available
De-identified Donor Data
- CML diagnosis confirmation and disease phase where documented
- Age, sex assigned at birth, and ethnicity
- Donor-reported allergy and infectious disease history
- TKI treatment history where documented
- Additional CML-specific metadata available on request
Applications
- BCR-ABL1 and clonal evolution cytogenetic studies
- TKI resistance mechanism and leukemic stem cell persistence research
- Treatment-free remission biomarker studies
- Marrow niche and leukemic stem cell microenvironment research
- Molecular response and residual disease assay development
Other Specimen Types
For matched marrow-derived material across conditions, see our human bone marrow mononuclear cells collection, and our CML PBMCs for peripheral blood-based studies.
Compliance and Quality Assurance
- IRB-approved and HIPAA-compliant protocols
- Electronic informed consent with 21 CFR Part 11-compliant e-signatures
- Documentation support available for regulatory review
Ordering & Customization
CML BMMCs are available in standard and custom cell quantities. For pricing, international orders, or documentation requirements, please contact our team to confirm compatibility with your country’s regulations.
Donor Metadata
- Verified diagnosis and clinical history
- Demographic data: age, sex assigned at birth, race/ethnicity
- Medication and treatment background when available
Compliance and Quality Assurance
- IRB-approved collections and standardized procedures
- 21 CFR Part 11-compliant e-consent system
- HIPAA-compliant data management
Ordering & Customization
Human Bone Marrow Mononuclear Cells are available in customizable aliquot sizes. For international orders or documentation needs, please contact learnmore@sanguinebio.com to confirm requirements and availability. We also work with multiple ordering platforms and distributors, learn more here.
Protocols & Documentation
-
Informed Consent Form (ICF)
Available upon request — confirms donor consent for research use and downstream commercialization.
Where can I find your complete catalog?
You can find our full product catalog here.
How long can samples be stored?
Storage depends on sample type but often cryopreserved samples stored in liquid nitrogen can be stored for years.
What customization options are available?
Extensive customization is available. To discuss your project request a quote or email us at learnmore@sanguinebio.com.
Do you offer prospective collections?
Sanguine offers flexible prospective collection services tailored to fit your research. For more information and to request a quote, please see: our prospective biospecimen collection services page.
What is the turnaround time for custom collections?
Timelines depend on condition, sample type, and I/E criteria but we often start collection within 2 weeks of signed agreement.
Do you have samples in stock?
YES - we have in-stock inventory. You can also email us at learnmore@sanguinebio.com as we continually get new samples in our inventory.
What does unique donor mean?
Each sample from a different individual - Unique donor means each sample comes from a different person, ensuring biological diversity in your study.
Are samples collected under IRB-approved protocols?
YES - "IRB-approved collection protocols" and IRB approval documentation available upon request. Sanguine utilizes two internationally-recognized IRBs (Advarra and WCG IRB) for review and approval.
Frequently Asked Questions
Ask a Question
Need a custom Bone Marrow Mononuclear Cells cohort?
Our scientific team can scope prospective collections with donor-specific I/E criteria, typically starting within 2 weeks of agreement.